SpectaCell's $6.5M Bet: The Cell Analysis Platform That Could Speed Up Cancer Cures

Jan de Vries · 2026-10-09

### A New Player in Cell Therapy Analytics SpectaCell, a Ghent-based startup, just launched with $6.5 million in seed funding. The company spun out of imec, VIB, and Ghent University, and it's on a mission to change how we analyze cells for immunotherapy development. The round was led by imec.xpand, with participation from PMV's Flanders Future Tech Fund, InnovationQuarter Capital, Qbic, and VIB. That's a lot of confidence for a company that's still in its early days. ### Why Cell Analysis Matters Immunotherapies are revolutionizing cancer treatment. They harness the immune system to fight diseases. But there's a catch: predicting which therapies will work in patients—and producing them consistently—is incredibly hard. "Breakthrough medicines need breakthrough tools," says Tony Montoye, CEO and co-founder of SpectaCell. "Researchers need to know much earlier which candidates deserve further investment and why." Current testing methods are slow and fragmented. They often measure indirect signals or averages across a sample, which can hide important differences between individual cells. That means promising treatments might be overlooked, and patients wait longer for effective therapies. ### How SpectaCell's Technology Works SpectaCell's platform combines chip-based imaging with data analysis to track individual cells at high resolution over time. No fluorescent labels needed—those can interfere with cell behavior. The result? Detailed insights in hours, not days. The company is developing a cartridge-based instrument that's easy to use. It's designed for pharmaceutical and biotech companies, as well as specialist manufacturers worldwide. The goal is a single platform that works from early research all the way to routine manufacturing quality checks. ### The Team and Vision Founded in 2026 by Mathieu Rabaey, Veronique De Vroey, Jan Van de Velde, and Tony Montoye, SpectaCell brings together deep expertise in life sciences and technology. Benoit Devogelaere, Partner at imec.xpand, believes in the vision: "SpectaCell brings together disruptive semiconductor technology, an experienced team, and a major commercial opportunity. We are convinced that SpectaCell can become essential to how new medicines are selected, developed, and produced." ### What's Next? With this fresh capital, SpectaCell plans to further develop and commercialize its platform. The company is targeting applications in cell therapies and T-cell engagers—treatments that help immune cells recognize and attack cancer. If successful, SpectaCell could set a new industry standard, making drug development faster and more efficient. And that means better medicines, sooner, for patients who need them. > "Together with our biopharma partners, we will turn that vision into a platform for developing better treatments more efficiently." – Tony Montoye ### The Bigger Picture This isn't just about one startup. It's about a shift in how we approach immunotherapy. By understanding individual cells better, we can make smarter decisions earlier, reduce waste, and ultimately save lives. SpectaCell's journey is one to watch.